Background: Endoscopic sinus surgery is often performed to improve delivery of topical medication into sinus cavities. Intranasal steroids are guideline recommended in post-surgical patients, and experiments with cadavers suggest that surgery improves delivery of drug into sinuses. Exhalation delivery systems (EDS) use a new mechanism for intranasal delivery and have been shown to reach superior/posterior regions of the nasal cavity better than nasal sprays in unoperated patients.
Introduction
Chronic rhinosinusitis (CRS) is a chronic inflammatory condition of the nasal cavity and paranasal sinuses. Corticosteroids are a mainstay of medical therapy in the management of CRS, because the broad anti-inflammatory activity addresses the continual production of inflammatory mediators and polyp formation in the nasal passages (1, 2) . For safety reasons, topically acting corticosteroids are preferred over oral corticosteroids for long-term management, and it is thought to be important to deliver the medication into the affected paranasal sinus cavities to ensure effective long-term management of CRS (1, 2) . However, due to the complex and convoluted nasal anatomy, unoperated sinuses are difficult to access with medication delivered with high-volume nasal rinses or nasal sprays compared with sinuses that have been surgically opened (2) (3) (4) . Endoscopic sinus surgery (ESS) is the standard for surgical treatment of CRS and is generally indicated when symptoms persist despite appropriate medical therapy (2, 3) . Surgery aims to establish a patent nasal airway and relieve sinus outflow obstruction, decrease the overall inflammatory load, and open the sinuses to allow for removal of debris/bacteria via irrigation and improved postoperative topical drug delivery (3) . Surgical approaches can range from dilation of the natural ostia to interventions that completely remodel the anatomy and drainage pathways, particularly aimed at improving access to the paranasal sinuses for delivery of topically acting drugs and for mechanical irrigation (1) . In addition to endoscopic maxillary antrostomy and ethmoidectomy, endoscopic frontal sinusotomy, including Draf II and Draf III, is indicated for patients with refractory forms of chronic frontal sinus disease (5) . The Draf II procedure involves resection of the floor of the frontal sinus from the nasal septum medially, to the lamina papyracea laterally. The dissection involves removal of the anterior face of the frontal recess. Thus, the frontal sinus ostium is enlarged to its maximum dimension.
The Draf III procedure can be easily distinguished from the Draf II procedure by the additional resection of the superior nasal septum and entire frontal sinus floor (Figure 1) .
The extent to which a liquid introduced by nasal delivery accesses the sinus cavities after surgery is dependent on a number of factors, including the head position, drug delivery device, and the degree of surgery (3) . High-volume, low-flow (HVLF) nasal irrigation (for example, using a squeeze bottle) may be more effective for distributing liquid-containing medication into the sinuses compared with low-volume delivery methods such as nasal sprays, nebulisers, or drops (3, 6) . There is evidence that saline irrigation is beneficial in treating the symptoms of CRS when used as the sole modality of treatment (7) . On this background, it has been advocated to add high-dose, topically acting corticosteroids (mainly budesonide) to the HVLF saline nasal irrigation to combine irrigation and drug delivery in post-surgical CRS.
Furthermore, computational fluid dynamics (CFD) simulations of sinus deposition of HVLF-delivered liquid suggest that frontal sinus deposition can be increased after the Draf III procedurebut with substantially reduced maxillary and ethmoid sinus penetration-with the simulations indicating that removal of superior and inter-sinus septa during Draf III unexpectedly causes irrigation fluid to spill prematurely across the resected septum, thus reducing the irrigation of other sinuses (8) .
Although the addition of corticosteroid to HVLF rinses conceptually addresses the desire to increase drug delivery to surgically opened sinuses, there is no combination of nasal irrigation with a corticosteroid that is approved by any regulatory agency.
There are also drawbacks, including the fact that HVLF rinses with added corticosteroid can be costly, inconvenient, sometimes uncomfortable, require training/education, and can be associated with a number of side effects. These include Eustachian tube dysfunction and local irritation in ≈25% of patients, post-irrigation rhinorrhea, and asymptomatic hypothalamicpituitary-adrenal axis suppression (3, 9, 10) . In addition, with regard to delivery of medication, HVLF devices are generally inefficient, with less than 3% of the delivered liquid and drug retained in the nasal cavity (4) . to regularise and, in some areas, stitch together the triangles that make the 3D surface; remove artefacts; and remove surfaces that were not related to the nasal cavities. Meshmixer's analysis module was used to ensure that the surface was complete and that the STL could be created into an STL solid file. The STL solid surface was exported as STL (solid) and sent to 3D printing.
The nasal geometry was made with a stereolithographic 3D printer (Objet 250; CATI, Buffalo Grove, IL, US). This geometry was placed in a box subsequently filled with a fluid, semitransparent, semisoft silicone (Andersen, Jessheim, Norway). After the silicone had dried, the silicone block was carefully sectioned with a sharp knife and the rigid stereolithographic material representing the air-filled sinonasal geometry was carefully broken into pieces and removed, leaving a transparent silicone replica of the post-surgical sinonasal cavity.
Deposition experiment methods
Experiments with HVLF in the Draf II and conventional nasal sprays were performed with the nasopharynx patent. The nozzle bottle was inserted tightly into the left nostril of the cast and, with 1 full squeeze of the bottle (≈80 mL), a steady-state liquid level with liquid escaping from the contralateral nostril and/ or the nasopharynx was reached in all HVLF experiments. EDS experiments were performed with a plug inserted in the nasopharynx to simulate velum closure, which occurs naturally during EDS delivery. Velum closure is desirable during HVLF sinonasal irrigations, but it is not always achieved in real-life conditionsas verified by liquid escaping into the oral cavity. In the CFD study using the Draf III geometry, calculations were performed
with the velum open (8) . A special jig allowed fixation of the cast .
EDS-FLU, studied in patients with and without prior surgery, has been found to be effective in both sub-populations, raising the interesting question of the degree of sinus deposition that is produced by EDS delivery (15) (16) (17) (18) . 
Materials and methods

Cast development
Two silicone casts of the nasal cavity and sinuses, representing the geometry of a 47-year-old male patient with CRS who had undergone revision ESS of the maxillary, ethmoid, and frontal sinuses, including first a Draf II procedure and a subsequent Draf III procedure, were made from a computed tomography (CT) scan using 3D printing (permission granted by the patient). The CT scan obtained following the Draf III procedure was previously used for CFD simulation of nasal irrigations (8) . The DICOM® files of the nasal cavities were loaded into medical image software, The internal surfaces of the casts were coated with a sensitive gel that changes color on contact with liquid (Sar-Gel®, Sartomer, Exton, PA, US). For HVLF, ≈80 mL was administered to the left side of the cast as was done in the CFD publication, only with inclination of the nasal floor first at 45° and then at 90° (8) .
For the conventional nasal spray condition, 2 sprays (0. Previous validation work with nasal sprays and Sar-Gel had
shown that the rate of color change is influenced by the time from exposure and volume of liquid reaching the surface (19) ; therefore, spray and EDS delivery were evaluated at a standardized 10 minutes after administration. The effect of humidity in ambient air and exhaled breath is a potentially confounding variable on the Sar-Gel color change observed during use of an EDS. To visualize and adjust for this effect, experiments were performed under similar ambient conditions using an empty EDS device (2 actuations) in the Draf II cast (Figure 4 ).
Results
Cast deposition results
As expected, conventional intranasal corticosteroid spray deposited liquid only in the anterior nasal segments, with similar deposition profiles in both Draf II and Draf III casts ( Figure 5 ).
HVLF irrigation exhibited different deposition profiles in Draf II
and Draf III casts, and head position had a significant effect on which sinuses were exposed to the irrigation liquid ( Figure 6 ). HVLF delivery to the frontal sinuses improves with a 90° head tilt; however, access to the maxillary and ethmoid spaces is reduced. EDS delivery was associated with deposition to the frontal sinuses along with the maxillary and surgically opened ethmoid sinuses in the Draf III cast.
Distribution of HVLF irrigation liquid in the Draf
Sinus surgery, recommended for medically refractory CRS patients, is intended to reduce inflammatory burden and to improve access of topically acting corticosteroids into the diseased paranasal sinuses (3) . Drug delivery approaches that improve deposition of drug into the sinuses and the sinus drainage pathways, such as irrigations and EDS, may be particularly beneficial for patients who do not experience sufficient symptom relief with conventional nasal sprays; however, deposition patterns with alternative delivery methods may be affected by the extent of sinus surgery. The findings of this study are consistent with those of a previously reported CFD study utilizing the same nasal/sinus geometry from which the Draf III cast was derived, suggesting consistency of results across study methods (8) .
Results following HVLF irrigation demonstrated that increased frontal sinus deposition after Draf III was achieved but, as previously demonstrated with CFD, at the expense of substantially reduced maxillary and ethmoid sinus penetration (8) . Although it is typically assumed that more extensive surgery leads to increased sinus penetration with nasal irrigations, these findings support the observations, using CFD in the same geometry, that the resected septum can act as an "escape path", Although HVLF treatment offers a good method for sinonasal irrigation and lavage, it is an inefficient approach to drug delivery due to the small fraction (2.5 ± 1.6%; range, 0%-6.6%) of fluid retained in the nasal cavity following administration of corticosteroid (4) . This implies that, for example, with 1 mg of budesonide diluted in a single administration, one might expect 30 to 40 µg to remain in the nose/sinuses, which would be less than the delivered dose of budesonide nasal spray for allergic rhinitis (albeit with a presumably superior pattern of distribution). In contrast, no liquid was observed to escape from the nasal/sinus spaces following drug administration by EDS into nasal casts, indicating that the full dose (372 µg [93 µg per actuation], XHANCE) remains in the nasal passages and sinus cavities. Adjusting for the 1.7× higher glucocorticoid receptor binding affinity (20) of fluticasone propionate, 372 μg is a comparatively high dose in the target region (16, 17, 21) .
In less extensive sinus surgery not involving opening of the frontal sinuses, penetration to the frontal sinuses is expected to be absent or minimal with all methods due to the narrow frontal channels. With enlarged maxillary openings and intact septum, the fraction entering the maxillary sinuses depends heavily on the size of the openings. With HVLF delivery, maxillary sinus penetration may occur, as has been shown by CFD (8) , but fluid trapped in the maxillary sinuses may be inconvenient and unacceptable to the patients due to potential issues with delayed drip-out (9) . With an intact septum, HVLF delivery can reach all surfaces including the ethmoid region if performed correctly in the 90 o position, but the dose remaining after delivery is expected to be even smaller than in a postsurgical geometry with larger mucosal surfaces (8) .
In non-surgical geometries, multiple studies have verified that conventional nasal sprays (Nasonex, Flonase) and nasal pMDIs (QNASL) deposit only in the anterior and lower segment of the nose (22) (23) (24) (25) (26) . In contrast, previous studies with EDS in both casts and in gamma studies have verified substantial and broad deposition to all mucosal nasal surfaces (27, 28) comparing Nasonex and EDS in a normal cast (27, 29) . The results from the extensive clinical trial program involving hundreds of patients with and without nasal polyps suggest that the enhanced deposition pattern translates into clinically relevant benefits for the patients with and without prior sinus surgery (15-17, 30, 31) . (19) , and comparative studies with empty devices under the same conditions support that the color changes 
